 | January 7th, 2010Fathom and 454 Life Sciences, a Roche Company, Develop Innovative WebsiteA revolutionary new sequencing platform from 454 Life Sciences, a Roche Company, is launching in 2010 with a dedicated website designed and built by Hartford-based Fathom. The product, the GS Junior System, addresses the growing demand for next-generation sequencing tools for biological and medical research in small to medium sized laboratories.
“This truly enabling technology is now affordable for nearly every research lab. The online presence Fathom has created for the GS Junior will be an important tool in marketing this advanced technology,” said Ulrich Schwoerer, Head of Global Marketing at 454 Life Sciences.
According to 454 Life Sciences, the GS Junior System makes next-generation sequencing readily available to the individual researcher, just as the PC brought computing to the masses. To complement the revolutionary technology, Fathom developed a dedicated online website that showcases the product's features and research capabilities.
"Working with the 454 Life Sciences team, we built an online presence that provides labs with a way to virtually interact with the features of the technology before bringing it in-house. The technology required more than stationary web pages to show the innovation and true product value," said David Louden, Fathom President and CEO.
The affordable bench top GS Junior System, which is no bigger than a typical laser printer, has performance and features tuned to fit the needs of small to medium sized laboratories. The technology brings gene sequencing capabilities to individual researcher, increasing opportunities for advancements in biological and clinical research beyond the larger labs.
While launching the new GS Junior System for smaller labs, 454 continues to extend the performance of the company's flagship Genome Sequencer FLX System. Fathom and 454 are in current discussions to continue partnering on future marketing initiatives for the GS Junior System or other projects.
To visit the GS Junior micro-site, visit www.gsjunior.com. For more information on 454 Sequencing Systems, visit www.454.com.
About Fathom
Fathom is a brand and creative firm that helps forward-looking organizations to cultivate and sustain the value they offer the world. Clients turn to Fathom when they need to reinvent or reinvigorate their brand. When bringing a brand to life, Fathom helps clients engage audiences by leveraging the best of online, print and event marketing. Fathom's clients include Yale, ConnectiCare, Wireless Zone, Aid to Artisans and more. More about Fathom can be found at: www.fathom.net.
Contact: Suzi Craig, Director of Marketing and Engagement
Fathom
100 Allyn Street, Floor 2
Hartford, CT 06103
+1 860 677 9737, ext. 6026
suzi@fathom.net
About 454 Life Sciences
454 Life Sciences, a center of excellence of Roche Applied Science, develops and commercializes the innovative 454 Sequencing System for ultra-high-throughput DNA sequencing. Specific applications include de novo sequencing and re-sequencing of genomes, metagenomics, RNA analysis, and targeted sequencing of DNA regions of interest. The hallmarks of the 454 Sequencing System are its simple, unbiased sample preparation and long, highly accurate sequence reads, including paired-end reads. The technology of the 454 Sequencing System has enabled hundreds of peer-reviewed studies in diverse research fields, such as cancer and infectious disease research, drug discovery, marine biology, anthropology, paleontology and many more.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2008 sales by the Pharmaceuticals Division totalled 36.0 billion Swiss francs, and the Diagnostics Division posted sales of 9.7 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority owwww.roche.comnership interests in Genentech and Chugai, and invested nearly 9 billion Swiss francs in R&D in 2008. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.
Contact: Katie Montgomery, Marketing Communications Specialist
454 Life Sciences
A Roche Company
15 Commercial Street
Branford, CT 06405
+1 203 871 2218
katie.montgomery@roche.com
 |
